LPL Financial
ALDX icon

LPL Financial’s Aldeyra Therapeutics ALDX Stock Holding History

LPL Financial’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.4K Sell
13,316
-10,100
-43% -$17.4K ﹤0.01% 6095
2026
Q1 		$39.6K Sell
23,416
-11,500
-33% -$50.4K ﹤0.01% 5808
2025
Q4 		$181K Hold
34,916
– – ﹤0.01% 5471
2025
Q3 		$182K Sell
34,916
-14,525
-29% -$75.7K ﹤0.01% 5379
2025
Q2 		$189K Buy
49,441
+173
+0.4% +$447 ﹤0.01% 5111
2025
Q1 		$283K Sell
49,268
-10,220
-17% -$60.4K ﹤0.01% 4612
2024
Q4 		$297K Buy
59,488
+38,702
+186% +$199K ﹤0.01% 4535
2024
Q3 		$112K Sell
20,786
-550
-3% -$2.62K ﹤0.01% 4874
2024
Q2 		$70.6K Buy
21,336
+958
+5% +$3.75K ﹤0.01% 4794
2024
Q1 		$66.6K Buy
20,378
+1,556
+8% +$5.12K ﹤0.01% 4734
2023
Q4 		$66.1K Buy
+18,822
New +$58.1K ﹤0.01% 4618
2021
Q3 		– Sell
-14,036
Closed -$159K – 4323
2021
Q2 		$159K Sell
14,036
-16,049
-53% -$193K ﹤0.01% 3964
2021
Q1 		$357K Buy
+30,085
New +$346K ﹤0.01% 3335

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $214M AUM 62.74% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

LPL Financial's ALDX Position: Q2 2026 in Review

LPL Financial reduced its Aldeyra Therapeutics (ALDX) stake by 43% in Q2 2026, selling an estimated $17.4K and leaving 13,316 shares worth $28.4K. The position accounts for ﹤0.01% of the portfolio, ranked #6095.

LPL Financial first reported a position in ALDX in Q1 2021 and has held it in 13 quarters since. The position peaked at $357K in Q1 2021. 107 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • LPL Financial held 13,316 shares of Aldeyra Therapeutics worth $28.4K as of Q2 2026.
  • LPL Financial sold 10,100 Aldeyra Therapeutics shares in Q2 2026, an estimated $17.4K.
  • Aldeyra Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q2 2026, its #6095 holding.
  • LPL Financial first reported a position in Aldeyra Therapeutics in Q1 2021 and has held it in 13 quarters since.
  • LPL Financial's Aldeyra Therapeutics position peaked at $357K in Q1 2021.
  • 107 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on LPL Financial's 13F filing for Q2 2026, filed 7 Aug 2026.